Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients

Sammy Saab, Adam Greenberg, Edwin Li, Sherona Ngashea Bau, Francisco Durazo, Mohammed El-Kabany, Steven Han, Ronald W. Busuttil

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Background and Aims: Hepatitis C is the most common indication for liver transplantation (LT). Recurrent infection is universal and can lead to progressive liver disease. Widespread use of interferon-based therapy has been limited by intolerability and adverse effects. Methods: We retrospectively evaluated the safety, tolerability, and efficacy of sofosbuvir and simeprevir in the treatment of recurrent hepatitis C in adult (age >18) LT recipients. Results: Seventy-six percent of the recipients were male and the mean age [±standard deviation (SD)] was 61 (±6.0) years. The mean time (±SD) from LT to treatment initiation was 71.8 (±77.1) months. Of the 26 patients with viral levels measured 4 weeks after starting antiviral therapy, 58% were undetectable. At the end of therapy, viral load was undetectable in all transplant recipients. The 12 week sustained viral response (SVR) was 93%. All recipients were able to complete therapy and no patients required growth factors of blood product transfusion during treatment. No patient required drug interruption of their immunosuppressant therapy. Conclusion: The use of sofosbuvir and simeprevir is efficacious, safe, and tolerable and should be considered in LT recipients with recurrent HCV who are candidates for antiviral therapy.

Original languageEnglish (US)
Pages (from-to)2442-2447
Number of pages6
JournalLiver International
Issue number11
StatePublished - Nov 2015


  • Antiviral therapy
  • Hepatitis C
  • Liver transplant recipients

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients'. Together they form a unique fingerprint.

Cite this